Viral Vector Gene Therapies

All Viral Vector Services

The success of your program hinges on your process resiliency. Minaris Advanced Therapies can partner with you from early construct design to clinical supply, and ultimately commercial GMP production. Our experts integrate process development with proprietary platform technologies to increase yields, enhance consistency, and streamline tech transfer. We offer scalable manufacturing from 50L to 2,000L, supported by a global supply chain network, regulatory-ready documentation, comprehensive analytical testing, and quality systems aligned with international standards. 

Learn More

Viral Vector Platforms

Every program is unique and presents distinct challenges and objectives. At Minaris Advanced Therapies, we deliver custom viral vector services tailored to your goals, challenges, and timelines.

Our breakthrough TESSA® technology for scalable AAV production offers flexibility across formats, scales, and process steps — supported by advanced analytics for data-driven decisions. For AAV programs requiring additional optimization, our gene silencing technology can be applied through traditional triple transfection or seamlessly integrated with TESSA®, providing adaptable approaches aligned with your strategic objectives.

We partner with you to unlock the highest yield, titre, and quality, accelerating your path from concept to clinic.

Learn More

Testing Services

With over 40 years of testing experience, our analytical teams will help you design a comprehensive release program for unprocessed bulk, drug substance, and drug product. We offer a complete panel of safety, purity, and identity methods to ensure the final therapeutic product is compliant and ultimately ready for patient delivery. In addition to release assays, Minaris Advanced Testing can also design and execute your drug substance and drug product stability studies or perform characterization assays such as TEM.

Whether your LVV or AAV is intended to be the drug product or an ex vivo gene delivery or editing tool, our team of analytical development experts can optimize and execute your critically important viral potency assays. Our team has years of experience transferring potency assays in-house, optimizing, qualifying, validating, and conducting comparability studies.

Learn More
Delivering Scalable, High-Quality Vector Design and Manufacturing

Viral vectors, especially adeno-associated virus (AAV) and lentivirus (LVV), are essential ex-vivo and in-vivo delivery systems for many advanced therapies, requiring precision engineering, robust GMP manufacturing, and rigorous quality control.

Minaris Advanced Therapies supports innovators across every stage of viral vector development — from early research through commercial supply — delivering complete CMC solutions, with product quality at the core. Our teams bring deep expertise in vector design, process and analytical development, GMP manufacturing and product release and leverage our proprietary platforms and technologies to help therapy developers reduce risk, accelerate timelines, and reach patients faster.

Connect With Our Experts

Viral Vector Technologies

We leverage proprietary innovations to achieve the scale and quality needed to support your programs: TESSA® delivers fully scalable, high-yielding AAV production, while XOFLX™ ensures stable LVV packaging. These next-generation platforms deliver significantly higher yields, greater purity, and superior process reliability compared to traditional transient transfection. By reducing manufacturing costs per dose by over 20-fold, improving control over starting materials, and simplifying scale-up, TESSA® and XOFLX™ deliver the performance and reliability required to accelerate the global delivery of advanced therapies to patients.

Explore All Viral Vector Technologies

Viral Vector Plasmid Technologies

Whether you are developing an LVV or an AAV, our team of expert scientists can work with you to optimize your plasmid architecture to achieve higher titers, fewer impurities, improved product quality, and robust regulatory compliance, ultimately enabling a faster transition from discovery to IND. Our plasmid design and engineering services can integrate seamlessly with our established platforms or be offered as standalone solutions to optimize your existing vector manufacturing approach.

Explore Plasmid Engineering

Technologies & Platforms

Explore our suite of enabling technologies to strengthen every stage of your therapy’s lifecycle from payload design and vector production to analytical testing and platform optimization.

icon

Plasmid Engineering

Design optimized backbones to improve expression, control, and vector performance from day one.
icon

TESSA® AAV Production Technology

Boost AAV yields while reducing helper virus risk with our helper-free Tessa platform.
icon

XOFLX™ Lentiviral Packaging & Producer Cell Lines

Accelerate lentiviral development with stable packaging and producer lines built for scale.
icon

Viral Vector Technologies

Explore vector-specific innovations that improve quality, titer and safety.
icon

Cell Therapy Technologies

Leverage modular, closed-system solutions for consistent and compliant cell therapy manufacturing.
icon

Testing Technologies

Enhance product understanding and regulatory readiness with high-sensitivity analytical platforms.

Knowledge Center

Explore More Resources

Through our Knowledge Center, we share data-driven insights and best practices from across the industry to help you stay ahead of evolving expectations.

See all resources

Contact Us

Minaris Advanced Therapies is dedicated to helping innovators in cell and gene therapy succeed. Whether you are in early-stage development or preparing for commercial launch, our end-to-end expertise, global reach and commitment to quality make us the ideal partner for cell and gene therapy manufacturing and GMP biosafety and analytical testing of all biologics.

Get in Touch